Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Neoplasms 31Neoplasm Metastasis 28Carcinoma 18Colorectal Neoplasms 16Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14NSCLC 14Adenocarcinoma 11Melanoma 10Lung Diseases 10Brain Neoplasms 10Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8Respiratory Tract Neoplasms 7Non-Squamous Non-Small Cell Lung Cancer 7Neoplasms by Site 7Bronchial Neoplasms 7Respiratory Tract Diseases 6Ovarian Neoplasms 6Neoplasms by Histologic Type 6Meningeal Carcinomatosis 6Squamous Cell Carcinoma of Head and Neck 5Solitary Fibrous Tumor, Pleural 5

Interventions

amatuximab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Severe combined immunodeficiency with sensitivity to ionizing radiation × Pemetrexed × Thoracic × Clear all
NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡